1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. WuXi AppTec Co., Ltd.
  6. Summary
    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-06-30
102.80 CNY   -1.14%
06/22Sirona Biochem Contracts WuXi AppTec to Manufacture Anti-Aging Compound for Clinical Trial; Pursues Licensing Deal
MT
06/16WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies
AQ
06/13WuXi Apptec's Founder Affiliates to Offload Up to 3% Stake in Firm; Shares Plunge 10%
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
103.46 102.15 101.43 103.99 102.8 Last
36200220 23500520 21958750 25647800 18685300 Volume
+0.77% -1.27% -0.70% +2.52% -1.14% Change
Estimated financial data (e)
Sales 2022 38 383 M 5 728 M 5 728 M
Net income 2022 7 828 M 1 168 M 1 168 M
Net cash position 2022 7 003 M 1 045 M 1 045 M
P/E ratio 2022 38,2x
Yield 2022 0,69%
Sales 2023 46 465 M 6 934 M 6 934 M
Net income 2023 9 841 M 1 469 M 1 469 M
Net cash position 2023 8 801 M 1 313 M 1 313 M
P/E ratio 2023 31,1x
Yield 2023 0,85%
Capitalization 299 B 44 566 M 44 566 M
EV / Sales 2022 7,60x
EV / Sales 2023 6,24x
Nbr of Employees 36 997
Free-Float 63,7%
More Financials
Company
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing... 
More about the company
Ratings of WuXi AppTec Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about WUXI APPTEC CO., LTD.
06/22Sirona Biochem Contracts WuXi AppTec to Manufacture Anti-Aging Compound for Clinical Tr..
MT
06/16WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel..
AQ
06/13WuXi Apptec's Founder Affiliates to Offload Up to 3% Stake in Firm; Shares Plunge 10%
MT
06/12WuXi AppTec Falls Sharply as Shareholders Plan to Sell Stake
DJ
06/05WuXi AppTec Co., Ltd. Reiterates Earnings Guidance for the Second Quarter of 2022
CI
05/25WuXi AppTec Co., Ltd. Announces Management Changes
CI
05/17WuXi Apptec Eyes Issue of Over 78 Million Shares in Hong Kong Under Mandate
MT
05/06WuXi AppTec Co., Appoints Minzhang Chen as Director
CI
05/06WuXi AppTec Co Announces Dividend for 2021, Expected Payable Date of H Shareholders Jun..
CI
04/28UBS Adjusts WuXi AppTec's Price Target to HK$173 From HK$192, Keeps at Buy
MT
04/26WuXi AppTec's Q1 Profit Rises 9.5% on Revenue Growth; Shares Jump 6%
MT
04/25WUXI APPTEC : First Quarter 2022 Results Presentation
PU
04/11WUXI APPTEC : POSITIVE PROFIT ALERT for First Quarter 2022 Results
PU
04/10WuXi AppTec Co., Ltd. Provides Earnings Guidance for the First Quarter Ended March 31, ..
CI
04/07WUXI APPTEC : Recognized as Top-Rated ESG Company by Sustainalytics
PU
More news
News in other languages on WUXI APPTEC CO., LTD.
06/22Sirona Biochem confie à WuXi AppTec la fabrication d'un composé anti-âge destiné à un e..
06/13Le fondateur affilié de WuXi Apptec va céder jusqu'à 3 % de sa participation dans la so..
06/05WuXi AppTec Co., Ltd. réitère ses prévisions de bénéfices pour le deuxième trimestre de..
05/25WuXi AppTec Co., Ltd. annonce des changements de direction
05/17WuXi Apptec envisage l'émission de plus de 78 millions d'actions à Hong Kong dans le ca..
More news
Analyst Recommendations on WUXI APPTEC CO., LTD.
More recommendations
Chart WUXI APPTEC CO., LTD.
Duration : Period :
WuXi AppTec Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI APPTEC CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 102,80 CNY
Average target price 156,29 CNY
Spread / Average Target 52,0%
EPS Revisions
Managers and Directors
Min Zhang Chen Co-Chief Executive Officer & Executive Director
Qing Yang Co-CEO, Executive Director & Executive VP
Ge Li Chairman & President
Ellis Chu Co-Chief Financial Officer & Senior Vice President
Ming Shi Co-Chief Financial Officer
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.-13.31%44 566
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
BIONTECH SE-38.91%38 276
GENMAB A/S-10.23%21 607